Zacks Investment Research Upgrades Nephros (OTCMKTS:NEPH) to Buy
Zacks Investment Research upgraded shares of Nephros (OTCMKTS:NEPH) from a hold rating to a buy rating in a research note published on Friday, Zacks.com reports. The brokerage currently has $12.00 price target on the stock.
According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “
Separately, Maxim Group began coverage on shares of Nephros in a research report on Friday, October 4th. They set a buy rating and a $16.00 price target for the company.
Nephros (OTCMKTS:NEPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. The business had revenue of $2.31 million during the quarter. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%. On average, equities research analysts forecast that Nephros will post -0.63 earnings per share for the current fiscal year.
Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Article: After-Hours Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.